Linked Life Data

8264715

Source:http://linkedlifedata.com/resource/pubmed/id/8264715

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5-6
pubmed:dateCreated
1994-1-27
pubmed:abstractText
Thirteen children were treated for 16 cases of proven (8 cases) or suspected (8 cases) invasive fungal infections caused by Candida spp. (9 cases), Aspergillus spp. (3 cases) and mycetoma (1 case). The type of fungal infection was not identified in 3 cases. Liposomal amphotericin B (AmBisome) was instituted because of the failure of previous treatments in 9 cases, toxicity-associated amphotericin B therapy in 4 cases and renal insufficiency in 3 cases. AmBisome was given for a median of 19 days (range 3-55) with a mean cumulative dose of 1.8 +/- 1.3 g (+/- SD). Acute toxic side-effects were not seen in any patients. Slight increases in serum creatinine were seen in 3 cases during AmBisome therapy. No other side-effects were observed. Among 8 cases with proven invasive fungal infection, 6 were clinically cured, one had persistent fungi and one died after only 3 days of AmBisome therapy. Eradication of fungi was documented in 5 out of 6 cases. Among the 8 cases with presumed fungal infections, 6 were clinically cured, one improved and one died after 6 days of treatment. To conclude, AmBisome can safely be given to children with invasive fungal infections; side-effects are minimal and among those treated for at least a week, the overall cure rate was 86% (12 out of 14).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0933-7407
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
187-92
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:articleTitle
Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children.
pubmed:affiliation
Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't